CHRU de Nancy

Running trials

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  2025-523670-17-00· Phase 3· Source

• Recruiting

  A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  NCT07189325· Phase 3· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Source

• Recruiting

  DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

  NCT07275515· Phase 2· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Source

• Recruiting

  Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

  NCT05653635· Phase 2· Source

• Not yet recruiting

  Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms (OPIDYS-ALS).

  2025-522546-52-00· Phase 3· Source

• Active, not recruiting

  Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.

  NCT03524352· Phase 3· Source

• Recruiting

  Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

  NCT07563205· Source

• Recruiting

  Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

  NCT07072988· Phase 4· Source

• Not yet recruiting

  Occurrence of Severe Cardiac Rhythm and Conduction Disturbances in Emergency Department Patients With Non-ST Elevation Acute Coronary Syndrome

  NCT07112547· Source

• Recruiting

  Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)

  2024-519521-37-01· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Source

• Recruiting

  Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

  NCT07243132· Source

• Recruiting

  Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma

  NCT05653622· Phase 2· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Source

• Recruiting

  Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke

  NCT06768138· Phase 3· Source

• Recruiting

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

  NCT06916806· Phase 1· Source

• Active, not recruiting

  An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

  NCT06617793· Phase 1/2· Source

• Recruiting

  Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction

  2023-508798-94-00· Phase 3· Source

• Not yet recruiting

  Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

  NCT06663189· Phase 3· Source

• Recruiting

  Hypertension induced by intravenous administration of norepinephrine to improve the prognosis of patients with neurological deterioration in the acute phase of an ischemic stroke

  2023-508704-37-00· Phase 3· Source

• Recruiting

  LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY

  2024-516433-13-00· Phase 3· Source

• Recruiting

  PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes

  NCT06338878· Source

• Recruiting

  Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy

  NCT06105645· Source

• Recruiting

  EWALL-PH OBSERVARTORY 2022

  NCT07684131· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Source

• Active, not recruiting

  Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

  NCT05753384· Phase 3· Source

• Active, not recruiting

  Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

  NCT06071091· Source

• Recruiting

  Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

  NCT05674994· Phase 3· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Recruiting

  Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

  NCT05476991· Phase 3· Source

• Recruiting

  Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

  NCT05521776· Source

• Recruiting

  Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults

  NCT05157685· Phase 3· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Source

• Recruiting

  Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

  NCT05105633· Phase 2/3· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· Source

• Recruiting

  TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

  NCT03910738· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Source

• Active, not recruiting

  Paediatric Hepatic International Tumour Trial

  NCT03017326· Phase 3· Source

• Recruiting

  Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

  NCT03268668· Source

• Active, not recruiting

  Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

  NCT02490904· Phase 3· Source

• Recruiting

  New CSF Biomarkers for Alzheimer's Disease

  NCT03621839· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke9 recruiting
• Multiple sclerosis8 recruiting
• Alzheimer disease2 recruiting
• Childhood cancers2 recruiting
• Coronary artery disease2 recruiting
• Glioblastoma2 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• Lupus (SLE)2 recruiting
• Myasthenia gravis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Epilepsy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Primary biliary cholangitis1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Source

• Completed

  PASSPORT

  NCT06274294· Phase 3· Source

• Completed

  “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis”

  2023-503289-22-00· Phase 2· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· Source

• Completed

  Predictive Factors for a Positive Exercise Bronchial Hyperresponsiveness Test

  NCT07766460· Source

• Completed

  Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

  2023-509615-92-00· Phase 2· Source

• Completed

  Millipede AspiRation for Revascularization in Stroke (MARRS) Study

  NCT05714501· Source

• Completed

  A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

  NCT03966651· Phase 1· Source

• Completed

  Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI

  NCT06037343· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

  NCT05559398· Phase 2/3· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Source

• Active, not recruiting

  Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  NCT04150497· Phase 1/2· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source